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Those randomized to the intervention group increased their 6-minute
walk distance in meters signiﬁcantly (357.4 to 399.8 vs 353.3 to 342.2
for those in the control group; mean difference, 53.5; P < .001). There
were also increases in maximum treadmill walking time (intervention,
7.91 to 9.44 minutes vs control, 7.56 to 8.09 minutes; mean difference,
1.01 minutes; P ¼ .04). Accelerometer-measured physical activity over 7
days also increased in the intervention group vs the control group (P ¼
.03). There were also signiﬁcant improvements in the Walking Impairment
Questionnaire distance score (P ¼ .003) and Walking Impairment Ques-
tionnaire speed score (P ¼ .004).
Comment: The study indicates that home-based exercise can be
effective in patients with PAD. It does not indicate that home-based exercise
has equal effectiveness to supervised exercise programs, because the two
were not directly compared. Nevertheless, until supervised exercise becomes
a beneﬁt of insurance coverage, the data should encourage physicians to
recommend home-based exercise therapy in their patients with PAD.
Use of Glucocorticoids and Risk of Venous Thromboembolism: A
Nationwide Population-Based Case-Control Study
Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. JAMA Intern
Med 2013;173:743-52.
Conclusions: Glucocorticoid use increases the risk of venous throm-
boembolism (VTE).
Summary: It is known that excess endogenous cortisol increases VTE
risk. Whether this risk applies to exogenous use of glucocorticoids is
unclear, however, potentially clinically important. The authors point out
that in Denmark, the country of origin of this study, 3.5% of the population
redeemed a prescription for systemic glucocorticoids in 2010 (Danish
Medicines Agency). Given the incidence of VTE and the prevalence of
glucocorticoid use, any association between VTE and glucocorticoid use
has important implications. The authors therefore decided to examine the
association between exogenous glucocorticoid use and VTE. This was
a population case-control study using a nationwide database from
Denmark. The authors identiﬁed 38,765 VTE cases from the period of
January 1, 2005, through December 31, 2011. Risk matched sampling
by birth year and sex was used to select 387,650 controls from the general
population. The VTE diagnosis date for the case was the index date for
cases and matched controls. Patients who had ﬁlled a glucocorticoid
prescription were classiﬁed by the time the prescription was ﬁlled, #90
days, 91 to 365 days, and >365 days before the index VTE date. Such
patients were classiﬁed as present, recent, and former users of glucocorti-
coids, respectively. Present users were subdivided into new (ﬁrst-ever
prescription <90 days before the index date) and continuing users (others).
Analysis was performed using conditional logistic regression adjusted for
VTE risk factors to estimate incidence rate ratios (IRRs) and 95% conﬁ-
dence intervals (CIs) for glucocorticoid users vs nonusers. VTE risk was
increased by systemic glucocorticoids in present (adjusted IRR, 2.31; 95%
CI, 2.18-2.45), new (3.06; 2.77-3.38), continuing (2.02; 1.88-2.17),
and recent (1.18; 1.10-1.26) users but not in former users (0.94; 0.90-
0.99). Adjusted IRR increased from 1.00 (95% CI, 0.93-1.07) for a prednis-
olone-equivalent cumulative dose of #10 mg to 1.98 (95% CI, 1.78-2.20)
for >1000 to 2000 mg, and to 1.60 (95% CI, 1.49-1.71) for doses >2000
mg. New use of inhaled (adjusted IRR, 2.21; 95% CI, 1.72-2.86) and intes-
tinal-acting (adjusted IRR, 2.17; 95% CI, 1.27-3.71) glucocorticoids also
increased VTE risk.
Comment: Of course, many of the disease processes for which gluco-
corticoids are prescribed may, in themselves, increase VTE risk. However,
this extensive analysis found increased risk for not only systemic glucocorti-
coids but also inhaled and intestinal-acting glucocorticoids, and a causal link
is further suggested by higher risk with new users, and with higher doses.
These observations, along with adjustment for confounding variables,
strongly suggest that the authors’ conclusion is correct that glucocorticoid
use increases the risk of VTE.
Ambulatory Blood Pressure Changes After Renal Sympathetic
Denervation in Patients with Resistant Hypertension
Mahfoud F, Ukena C, Schmieder RE, et al. Circulation 2013;124:132-40.
Conclusions: Ofﬁce blood pressures are reduced and relevant aspects
of ambulatory blood pressure (BP) monitoring (APBM) are improved after
renal sympathetic denervation in patients with true-treatment resistant
hypertension.
Summary: Hypertensive patterns and methods of assessing BP appear
to be important in the relationship between hypertension and cardiovascular
morbidity and mortality. Guidelines recommend ABPM for patients with
resistant hypertension. This is to exclude pseudohypertension and accurately
assess BP control according to treatment. ABPM, with 24-hour day-and-night average BP values, correlates better than ofﬁce BP values with hyper-
tensive or diabetic end-organ damage (Mancia G et al, Hypertension
2000;36:894-900). In addition, nighttime BP correlates more closely
with cardiovascular morbidity and mortality than daytime BP (Fagard RH
et al, Hypertension 2008;51:55-61). Finally, high nighttime BP and non-
dipping patterns of hypertension have been associated with increased
sympathetic activity in hypertensive patients (Grassi G et al, Hypertension
2008;52:925-31). Renal sympathetic denervation (RDN) reduces ofﬁce
systolic and diastolic BPs in patients with resistant hypertension (Esler
MD et al, Lancet 2010;376:1903-9). The purpose of this study was to
investigate the effects of RDN on out-of-ofﬁce BP using 24-hour ABPM.
The study represents the largest cohort of patients with true resistant and
pseudoresistant hypertension analyzed thus far. A total of 346 uncontrolled
hypertensive patients were separated according to daytime ambulatory BP
monitoring into 303 with true resistant BP (ofﬁce systolic BP [SBP] 172
6 22 mm Hg; 24-hour SBP 154 6 16 mm Hg) and 43 with pseudoresist-
ant hypertension (ofﬁce SBP 161 6 20.3 mm Hg; 24-hour SBP 121 6 20
mm Hg). Patients were from 10 centers and were studied at 3, 6, and 12
months of follow-up after RDN. In follow-up, ofﬁce SBP was reduced by
21.5/23.7/27.3 mm Hg, ofﬁce diastolic BP by 8.9/9.5/11.7 mm Hg,
and pulse pressure by 13.4/14.2/14.9 mm Hg (n ¼ 245/236/90; P for
all <.001), respectively, at 3, 6, and 12 months. In patients with true treat-
ment resistance, there was a signiﬁcant reduction with RDN in 24-hour SBP
(0.1/10.2/11.7) and minimum SBP (6.0/9.4/13.1 mm Hg; P
< .001) at 3, 6, and 12 months, respectively. In pseudoresistant patients,
RDN had no effect on ambulatory BP; however, ofﬁce BP was reduced
to a similar extent. RDN was equally effective in reducing BP in different
subgroups of patients. Ofﬁce SBP at baseline was the only independent
correlate of BP response.
Comment: The study addressed concerns that RDN might not as
effectively reduce ambulatory BP as it does ofﬁce BP. Results of the study
are not entirely unexpected. The Symplicity study of resistant hypertension
and RDN did not speciﬁcally exclude pseudoresistant hypertension (Esler
MD et al, Lancet 2010;376:1903-9). However, only w12% of the patients
in the Symplicity study apparently had pseudoresistant hypertension. As
treatment with RDN for resistant hypertension potentially moves toward
application out of clinical trials, it will be important for clinicians to be aware
that only patients with truly resistant hypertension, and not those with
“white-coat syndrome,” be considered for RDN.
Endovascular Repair Versus Open Repair of Ruptured Abdominal
Aortic Aneurysms: A Multicenter Randomized Controlled Trial
Reimerink JJ, Hoornweg LL, Vahl AC, and the Amsterdam Acute
Aneurysm Trial Collaborators. Ann Surg 2013;258:248-56.
Conclusions: There is no difference in outcome of treatment of
ruptured abdominal aortic aneurysm (RAAA) in rates of death and severe
complication for those patients treated with endovascular (EVAR) or
open repair (OR).
Summary: In recent years, treatment of RAAA with EVAR has
emerged as an alternative to OR. Support for the hypothesis that EVAR
reduces mortality in patients with RAAA vs those treated with OR comes
from observational and population-based studies (Veith FJ, Ann Surg
2009;250:818-24; and Giles KA, J Endovasc Ther 2009;16:554-64).
However, to date, no signiﬁcant randomized trial data has been available
comparing EVAR vs OR for RAAA. A single previous trial was terminated
after randomizing 32 patients (Hinchliffe RJ et al, Eur J Vasc Endovasc Surg
2006;32:506-13). The Amsterdam Acute Aneurysm Trial was designed
with the hypothesis that EVAR would reduce mortality and severe compli-
cations compared with OR for treatment of RAAA. The study was conduct-
ed in the greater Amsterdam area (1.24 million inhabitants and 10
hospitals). Three hospitals, consisting of two academic medical centers
and a teaching hospital, were trial centers for this study. The trial centers
provided alternating around-the-clock RAAA service. The other seven
regional hospitals agreed to participate in the trial by transferring patients
with suspected RAAA to one of the trial centers if possible. They also
provided data on all patients who presented with an RAAA. After diagnosis,
anatomic suitability for EVAR based on computed tomography angiog-
raphy and clinical suitability for OR was documented by the vascular
surgeon and the radiologist. Patients suitable for both were then random-
ized. All patients in the trial region with proven RAAA were included in
a prospective parallel cohort. The primary end point of the study was the
composite of death and severe complications at 30 days. Between April
2004 and February 2011, 520 patients were identiﬁed with RAAA. Of these
patients, 365 were excluded from potential randomization because of
anatomy unfavorable for EVAR, another 71 were not evaluated by
computed tomography scan, and 54 were not referred to a trial center.
This left 155 with favorable anatomy who could potentially be randomized.
An additional 39 patients, however, were excluded as unﬁt for OR (n ¼ 16),
